- The European Commission has approved Merck & Co Inc's MRK Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy as first-line treatment of Esophageal Carcinoma or Gastroesophageal Junction (GEJ) Adenocarcinoma.
- The approval covers patients with locally advanced unresectable or metastatic carcinoma of the esophagus or HER2-negative GEJ adenocarcinoma whose tumors express PD-L1.
- This approval is based on results from the Phase 3 KEYNOTE-590 trial, in which Keytruda plus 5-fluorouracil (5-FU) and cisplatin demonstrated statistically significant improvements in overall survival (OS) and progression-free survival (PFS) compared with 5-FU and cisplatin alone in all pre-specified study populations.
- Price Action: MRK shares are up 0.22% at $77.03 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
